ArticleClinical pharmacokinetics2019
Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.
Article in Clinical pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Towards Model-Informed Precision Dosing of High-Dose Rifampicin: A Parsimonious Population Pharmacokinetic Model Capturing Saturation and Autoinduction in Tanzanian and South African Patients with Tuberculosis.Clinical pharmacokinetics · 2026Article
- Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.Antimicrobial agents and chemotherapy · 2023Article
- Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.Clinical pharmacokinetics · 2023Article
- Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study.European journal of drug metabolism and pharmacokinetics · 2023Article
- Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin.Pharmaceutics · 2022Article
- Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management.Pharmaceutics · 2022Review
- Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis.Pharmaceutics · 2022Article
- Article
- A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.Clinical pharmacokinetics · 2021Article
- Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.Clinical pharmacokinetics · 2021Review
- Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.Clinical pharmacokinetics · 2021Review
- Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review.Frontiers in pediatrics · 2021Review
- Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Perspective for Precision Medicine for Tuberculosis.Frontiers in immunology · 2020Review
- Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example.Frontiers in pharmacology · 2020Article
- Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.Frontiers in pharmacology · 2020Article
- Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.British journal of clinical pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThis study proposes a model-informed approach for therapeutic drug monitoring (TDM) of rifampicin to improve tuberculosis (TB) treatment.
methodsTwo datasets from pulmonary TB patients were used: a pharmacokinetic study (34 patients, 373 samples), and TDM data (96 patients, 391 samples) collected at Radboud University Medical Center, The Netherlands. Nine suitable population pharmacokinetic models of rifampicin were identified in the literature and evaluated on the datasets. A model developed by Svensson et al. was found to be the most suitable based on graphical goodness of fit, residual diagnostics, and predictive performance. Prediction of individual area under the concentration-time curve from time zero to 24 h (AUC
resultsA sampling strategy using 2- and 4-h blood collection was selected to be the most suitable. The bias and precision of the two strategies were comparable, except that the linear regression strategy was more biased in prediction of the AUC
conclusionBlood sampling at 2 and 4 h, combined with model-based prediction, can be used instead of the currently used linear regression strategy, shortening the sampling by 2 h and one sampling point without performance loss while simultaneously offering flexibility in sampling times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.